Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

Next Previous
Trial Profile

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atabecestat (Primary) ; E 2814 (Primary) ; Florquinitau F18 (Primary) ; Gantenerumab (Primary) ; Lecanemab (Primary) ; Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms DIAN-TU; DIAN-TU-001; Tau NexGen Study

    • Most Recent Events

    • 01 Jul 2023 Results (n=66) assessing Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in dominantly inherited Alzheimer's disease published in the European Journal of Nuclear Medicine and Molecular Imaging
    • 30 Nov 2022 According to media release, data from this study presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference
    • 27 Nov 2022 Planned End Date changed from 1 Jul 2022 to 1 Oct 2027.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top